Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 231-891-6 | CAS number: 7775-19-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://poisoncentres.echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Direct observations: clinical cases, poisoning incidents and other
Administrative data
- Endpoint:
- direct observations: clinical cases, poisoning incidents and other
- Type of information:
- other: Case study
- Adequacy of study:
- supporting study
- Study period:
- No data
- Reliability:
- other: Case study
- Rationale for reliability incl. deficiencies:
- other: Not applicable as this is a case study.
Data source
Referenceopen allclose all
- Reference Type:
- publication
- Title:
- Enquiries to a centre for information on poisoning during a period of 12 years (Boraks er de farlight (12 ars foresporgslert il giftinformationscentralen).
- Author:
- Adelhardt & Fogh A
- Year:
- 1 983
- Bibliographic source:
- Ugeskr. Laeger 145: 3808 - 3810.
- Reference Type:
- publication
- Title:
- Poisoning: Toxicology, symptoms, treatments.
- Author:
- Arena JM & Drew RH
- Year:
- 1 986
- Bibliographic source:
- Thomas Springfield, IL: P131.
- Reference Type:
- publication
- Title:
- Ingestion of boric acid by infants.
- Author:
- Baker MD & Bogema SC
- Year:
- 1 986
- Bibliographic source:
- Am. J. Emerg. Med. 4: 358.
- Reference Type:
- publication
- Title:
- Boric acid poisoning treated by exchange transfusion; report of a case.
- Author:
- Boggs TR & Anrode HG
- Year:
- 1 955
- Bibliographic source:
- Pediatrics 16: 109.
- Reference Type:
- publication
- Title:
- Boric acid poisoning in an infant.
- Author:
- Connelly JP, Crawford JD & Soloway AH
- Year:
- 1 958
- Bibliographic source:
- New England Journal of Medicine. 259: 1123.
- Reference Type:
- publication
- Title:
- Hazard assessment of boric acid in toys.
- Author:
- Craan AG, Myers AW & Green DW
- Year:
- 1 997
- Bibliographic source:
- Reg. Tox. Pharmacol. 26: 271 - 280.
- Reference Type:
- publication
- Title:
- Inorganic boron health effects in humans: An aid to risk assessment and clinical judgement.
- Author:
- Culver BD & Hubbard SA
- Year:
- 1 996
- Bibliographic source:
- J. Trace. Elements in Experimental Medicine 9: 175 - 184.
- Reference Type:
- publication
- Title:
- Un cas de dermatite exfoliante palmaire condsecutivea l'inestion d'acide borique.
- Author:
- Desage M
- Bibliographic source:
- Societe des Sciences Medicales et Biologique de Montpellier et du Languedoc Mediteranneen, Archives (bull. Soc. Sci. Med. Biol. (Montpellier) 4: 154.
- Reference Type:
- publication
- Title:
- Reevaluation de la toxicite des sodium borates. A propos de 134 observations au CAP de Paris.
- Author:
- Elmalem J, Efthymious ML & Fournier E
- Year:
- 1 984
- Bibliographic source:
- Toxicol. Med. 4: 317 - 325.
- Reference Type:
- publication
- Title:
- Boric acid poisoning in infants; cases observed at the Rome Pediatric Centre from 1958 - 1968.
- Author:
- Giadini O & Cardi E
- Year:
- 1 970
- Bibliographic source:
- Minerva Pediatr. 22: 1723 - 1726.
Materials and methods
- Study type:
- poisoning incident
- Endpoint addressed:
- not applicable
Test guideline
- Qualifier:
- no guideline required
- Principles of method if other than guideline:
- This is a summary of accidental or intentional poisoning incidents for humans.
- GLP compliance:
- no
Test material
- Reference substance name:
- Boric acid and sodium borates
- IUPAC Name:
- Boric acid and sodium borates
- Details on test material:
- - Name of test material: Boric acid and sodium borates
Constituent 1
Method
- Subjects:
- Males and females of various ages.
- Route of exposure:
- other: Not specified
- Reason of exposure:
- other: Accidental misuse as an antiseptic or as a treatment for conditions such as epilepsy. Also, misuse in the preparation of baby formula and the topical use of boric acid powder in infant has led to poisonings.
- Exposure assessment:
- not specified
Results and discussion
- Clinical signs:
- A review was carried out of 784 cases of boric acid ingestions from two poison control centres in the USA for the period 1981-1985. No patients developed severe toxicity symptoms, and 88 % of these cases were asymptomatic. Less severe common symptoms were vomiting, lethargy and diarrhoea. The authors concluded that acute boric acid ingestions produced minimal or no toxicity and that aggressive treatment is not necessary in most patients. No fatalities or severe manifestations of toxicity were observed, despite ingestions of up to 89 g.
All the case studies for both acute and chronic (adults and children) show a common range of symptoms that occur on exposure to boric acid and sodium borates. The most commonly seen symptoms are nausea, diarrhoea, vomiting and skin rashes (dermatitis). Acutely, in adults, as administered dose increases from a dose of 2 – 3 g boric acid (29 – 43 mg boric acid/kg), or more, symptoms may include nausea, vomiting, diarrhoea, gastric discomfort, skin flushing, excitation, convulsions, depression and vascular collapse. In addition, cases where no real estimate of dose can be made, similar symptoms have been noted and especially vomiting and GI tract effects as the first symptom. In an extensive review by Kliegel (1980), single doses as low as 2-4 g have produced symptoms of vomiting and/or diarrhoea. In children, similar doses seem to produce the same symptoms. In the literature, the oral lethal dose is regularly quoted as of 2-3 g boric acid for infants, 5-6 g boric acid for children and 15-30 gm boric acid for to adults. Doses of 1-3 g have been reported as producing severe symptoms in infants (origin possibly McNally and Rust, 1928, McNally, and Rukstinat, 1947). However, there are cases where higher levels do not cause any serious effects, although medical intervention may have helped prevent the more severe symptoms (e.g. 88.8 g reported in Litovitz et al, 1988).
With chronic exposure in adults the symptoms seen most frequently at doses below around 3 g/day were dermatitis, nausea and in many cases vomiting, diarrhoea and indigestion. Doses above 3 –5 g/day regularly caused vomiting and/or diarrhoea in the first instance often accompanied by dermatitis and appetite suppression. As the dose became higher and the dosing period longer, symptoms of alopecia, disseminated maculopapular eruption followed by widespread desquamation and focal or generalised central nervous system irritation or convulsions occurred. The symptoms of dermatitis, nausea, diarrhoea and vomiting symptoms also occurred in some patients receiving doses of 2 g boric acid/day (29 mg boric acid/kg/day) and above. In one such case, reduction of the dose from 2 g/day of boric (29 mg boric acid/kg/day) acid to 1g/day (14 mg boric acid/kg/day) resulted in resolution of the effects (vomiting and dermatitis). In all cases where withdrawal of treatment was reported, recovery occurred with no lasting effects. The lowest recorded adult dose causing symptoms was 2 g/day boric acid.
In children, where low levels can be estimated, (Gordon et al, 1973 and O'Sullivan and Taylor, 1983), infants aged from 6 to 19.5 weeks ingested borax (as a honey-borax mixture which had been applied to pacifiers) for periods of 4 to 12 weeks. The mean intake was 0.98 g boric acid/day (range 0.55g to 2 g) for a 10 kg child. The effects seen, which disappeared on withdrawal of the honey-borax mixture, were of central nervous system signs, convulsions, generalized seizures and focal seizures. There were no dermal effects. Minor occurrences of vomiting and loose stools were also described. Further support for the initial symptoms of diarrhoea, vomiting, nausea as a result of exposure to boric acid or sodium borates comes from cases where patients have had sodium borates used as antiseptics for wound and body washes. The absorbed dose cannot be estimated. The first symptoms seen are GI effects including vomiting and diarrhoea indicating that the early effects of absorption of boric acid or sodium borates are vomiting. Similarly, in cases where infants have been liberally treated with neat boric acid powder on severe nappy rash or eczema (reviewed in Valdes-Dapena & Arey, 1962 and Gold 1949) which resulted in death in many cases, the early symptoms included vomiting and diarrhoea. - Results of examinations:
- A review was carried out of 784 cases of boric acid ingestion from two poison control centres in the USA for the period 1981-1985. No patients developed severe toxicity symptoms, and 88 % of these cases were asymptomatic. Less severe common symptoms were vomiting, lethargy and diarrhoea. The authors concluded that acute boric acid ingestion produced minimal or no toxicity and that aggressive treatment is not necessary in most patients. No fatalities or severe manifestations of toxicity were observed, despite ingestion of up to 89 g.
All the case studies for both acute and chronic (adults and children) show a common range of symptoms that occur on exposure to boric acid and sodium borates. The most commonly seen symptoms are nausea, diarrhoea, vomiting and skin rashes (dermatitis). Acutely, in adults, as administered dose increases from a dose of 2 – 3 g boric acid (29 – 43 mg boric acid/kg), or more, symptoms may include nausea, vomiting, diarrhoea, gastric discomfort, skin flushing, excitation, convulsions, depression and vascular collapse. In addition, cases where no real estimate of dose can be made, similar symptoms have been noted and especially vomiting and GI tract effects as the first symptom. In an extensive review by Kliegel (1980), single doses as low as 2-4 g have produced symptoms of vomiting and/or diarrhoea. In children, similar doses seem to produce the same symptoms. In the literature, the oral lethal dose is regularly quoted as of 2-3 g boric acid for infants, 5-6 g boric acid for children and 15-30 gm boric acid for to adults. Doses of 1-3 g have been reported as producing severe symptoms in infants (origin possibly McNally and Rust, 1928, McNally, and Rukstinat, 1947). However, there are cases where higher levels do not cause any serious effects, although medical intervention may have helped prevent the more severe symptoms (e.g. 88.8 g reported in Litovitz et al, 1988).
With chronic exposure in adults the symptoms seen most frequently at doses below around 3 g/day were dermatitis, nausea and in many cases vomiting, diarrhoea and indigestion. Doses above 3 –5 g/day regularly caused vomiting and/or diarrhoea in the first instance often accompanied by dermatitis and appetite suppression. As the dose became higher and the dosing period longer, symptoms of alopecia, disseminated maculopapular eruption followed by widespread desquamation and focal or generalised central nervous system irritation or convulsions occurred. The symptoms of dermatitis, nausea, diarrhoea and vomiting symptoms also occurred in some patients receiving doses of 2 g boric acid/day (29 mg boric acid/kg/day) and above. In one such case, reduction of the dose from 2 g/day of boric (29 mg boric acid/kg/day) acid to 1g/day (14 mg boric acid/kg/day) resulted in resolution of the effects (vomiting and dermatitis). In all cases where withdrawal of treatment was reported, recovery occurred with no lasting effects. The lowest recorded adult dose causing symptoms was 2 g/day boric acid.
In children, where low levels can be estimated, (Gordon et al, 1973 and O'Sullivan and Taylor, 1983), infants aged from 6 to 19.5 weeks ingested borax (as a honey-borax mixture which had been applied to pacifiers) for periods of 4 to 12 weeks. The mean intake was 0.98 g boric acid/day (range 0.55g to 2 g) for a 10 kg child. The effects seen, which disappeared on withdrawal of the honey-borax mixture, were of central nervous system signs, convulsions, generalized seizures and focal seizures. There were no dermal effects. Minor occurrences of vomiting and loose stools were also described. Further support for the initial symptoms of diarrhoea, vomiting, nausea as a result of exposure to boric acid or sodium borates comes from cases where patients have had sodium borates used as antiseptics for wound and body washes. The absorbed dose cannot be estimated. The first symptoms seen are GI effects including vomiting and diarrhoea indicating that the early effects of absorption of boric acid or sodium borates are vomiting. Similarly, in cases where infants have been liberally treated with neat boric acid powder on severe nappy rash or eczema (reviewed in Valdes-Dapena & Arey, 1962 and Gold 1949) which resulted in death in many cases, the early symptoms included vomiting and diarrhoea.
Applicant's summary and conclusion
- Conclusions:
- All the case studies for both acute and chronic (adults and children) show a common range of symptoms that occur on exposure to boric acid and sodium borates. The most commonly seen symptoms are nausea, diarrhoea, vomiting and skin rashes (dermatitis). Acutely, in adults, as administered dose increases from a dose of 2 – 3 g boric acid (29 – 43 mg boric acid/kg), or more, symptoms may include nausea, vomiting, diarrhoea, gastric discomfort, skin flushing, excitation, convulsions, depression and vascular collapse. In addition, cases where no real estimate of dose can be made, similar symptoms have been noted and especially vomiting and GI tract effects as the first symptom.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)